Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00.

Elisabetta MunzoneKathryn P GrayCaterina FumagalliElena Guerini-RoccoIstván LángThomas RuhstallerLorenzo GianniRoswitha KammlerGiuseppe VialeAngelo Di LeoAlan S CoatesRichard D GelberMeredith M ReganAron GoldhirschMassimo BarberisMarco Colleoni

Published in: Breast cancer research and treatment (2018)

Mutations in the tested oncogenes were not associated with breast cancer recurrence in this TNBC subset of patients. The question of whether any of these mutated genes (e.g., PIK3CA) may represent a useful therapeutic target in TNBC may be answered by ongoing clinical trials and/or larger dataset analysis.

Keyphrases

clinical trial
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
phase ii
study protocol
phase iii
gene expression
randomized controlled trial
dna methylation
young adults
transcription factor
open label
patient reported